MTOR and metastatic neoplasm: Although molecular targeted therapies (MTTs), such as mammalian target of rapamycin (mTOR) inhibitors and tyrosine kinase inhibitors, have been shown to improve outcomes in patients with metastatic disease, resistance to molecular targeted therapies often occurs [2, 3].